2.38
+0.01 (+0.42%)
Overall HTBX gets a fundamental rating of 2 out of 10. We evaluated HTBX against 525 industry peers in the Biotechnology industry. HTBX may be in some trouble as it scores bad on both profitability and health. HTBX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- HTBX had negative earnings in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.99% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HTBX does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | -1658.78% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- HTBX has more shares outstanding than it did 1 year ago.
- The debt/assets ratio for HTBX is higher compared to a year ago.
2.2 Solvency
- HTBX has an Altman-Z score of 2.71. This is not the best score and indicates that HTBX is in the grey zone with still only limited risk for bankruptcy at the moment.
- HTBX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.71 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- HTBX has a Current Ratio of 21.04. This indicates that HTBX is financially healthy and has no problem in meeting its short term obligations.
- HTBX has a Quick Ratio of 21.04. This indicates that HTBX is financially healthy and has no problem in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 21.04 | ||
| Quick Ratio | 21.04 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 9.62% over the past year.
- Looking at the last year, HTBX shows a very negative growth in Revenue. The Revenue has decreased by -28.09% in the last year.
- The Revenue has been growing by 44.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2600%
Revenue 1Y (TTM)-28.09%
Revenue growth 3Y-28.54%
Revenue growth 5Y44.1%
Sales Q2Q%2.18%
3.2 Future
- Based on estimates for the next years, HTBX will show a decrease in Earnings Per Share. The EPS will decrease by -0.56% on average per year.
- HTBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 136.46% yearly.
EPS Next Y-23.7%
EPS Next 2Y-3.24%
EPS Next 3Y10.19%
EPS Next 5Y-0.56%
Revenue Next Year128.57%
Revenue Next 2Y55.11%
Revenue Next 3Y129.35%
Revenue Next 5Y136.46%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- HTBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HTBX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.04 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.24%
EPS Next 3Y10.19%
5. Dividend
5.1 Amount
- No dividends for HTBX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSEARCA:HTBX (5/2/2022, 8:04:01 PM)
2.38
+0.01 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-11 2022-03-11/amc
Earnings (Next)05-17 2022-05-17/bmo
Inst Owners1.57%
Inst Owner Change0%
Ins Owners5.77%
Ins Owner Change0%
Market Cap61.05M
Revenue(TTM)2.11M
Net Income(TTM)-35.07M
Analysts82
Price Target11.6 (387.39%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 28.88 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | 1.04 |
EPS(TTM)-1.41
EYN/A
EPS(NY)-1.74
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.08
BVpS4.41
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.99% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | -1658.78% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 21.04 | ||
| Quick Ratio | 21.04 | ||
| Altman-Z | 2.71 |
F-Score0
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2600%
EPS Next Y-23.7%
EPS Next 2Y-3.24%
EPS Next 3Y10.19%
EPS Next 5Y-0.56%
Revenue 1Y (TTM)-28.09%
Revenue growth 3Y-28.54%
Revenue growth 5Y44.1%
Sales Q2Q%2.18%
Revenue Next Year128.57%
Revenue Next 2Y55.11%
Revenue Next 3Y129.35%
Revenue Next 5Y136.46%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
HEAT BIOLOGICS INC / HTBX FAQ
What is the ChartMill fundamental rating of HEAT BIOLOGICS INC (HTBX) stock?
ChartMill assigns a fundamental rating of 4 / 10 to HTBX.
What is the valuation status for HTBX stock?
ChartMill assigns a valuation rating of 3 / 10 to HEAT BIOLOGICS INC (HTBX). This can be considered as Overvalued.
How profitable is HEAT BIOLOGICS INC (HTBX) stock?
HEAT BIOLOGICS INC (HTBX) has a profitability rating of 1 / 10.